UnaCom Oil and Gas news
29th Oct- 4th Nov
Monday 29th October
North Sea Future Oil and Gas Projects to total £34bn in the next 7 years
Two studies have recently been undertaken and their results suggest that there could be a boost in investments in the near future. Energy companies will spend more than £31bn on new North Sea Projects over the next seven years. A total of 67 projects to be operated by four countries are expected to begin in operations between 2018-2025. The new project investment is expected to be worth £33.6bn of which £14.7bn will be spent to bring the projects online and the remaining amount of £18.9bn will be spent on key announced schemes. The UK leads the way in terms of the number of planned oil and gas projects with 11 in the pipeline with Norway and Netherlands following behind with 8 and 2 respectively. Norway is expected to be the biggest investor with £16.6bn between 2018 and 2025, comprising £10bn on key planned projects plus £6.6bn on announced projects. The UK comes a close second with a planned £15.8bn in capital expenditure, which includes £4.4bn on key planned projects and £11.4bn on announced projects during the same period. Research from the University of Aberdeen has predicted forecasts for energy production off Scotland’s coast to be up to 17 billion barrels of oil to be extracted between 2018 and 2050.
Tuesday 30th October
Prospects still high for the North Sea
There have been numerous stories over the years about the demise of the North Sea, yet they have been consistently wrong with predicting the eventual date when it will be finally out of use for good. Admittedly is has passed its peak, with only this year four exploratory wells having been drilled in the first eight months of 2018, with optimistic predictions for the end of the year to be 12 wells. This puts it at the same status as in 1965, which was just the second year of the modern era when exploratory work got underway. Every time an international company divests its assets in the North Sea, more news stories arise about the impending doom of the North Sea. However, if recent data is taken to be considered, Westwood Global Energy, forecasts that 17 exploration wells could be drilled on the U.K. continental shelf (UKCS) over the next 18 months, with a yield potential of over 2 billion barrels of oil equivalent. This is under half of what was drilled in 08-09, but it shows that the North Sea is nowhere near its end.
Wednesday 31st October
What does the budget mean for the Oil Industry in the North Sea?
The oil industry had no reason to be nervous for the budget announcement this week, with the Government having stated in the past to being committed to maximizing economic recovery from the UK continental shelf and stating they understand that higher tax rates play no role in achieving that objective. The Government has introduced new changes that make it possible for companies to transfer historical tax capacity as part of assets dispositions, thereby ensuring that new entrants or companies with no historic tax capacity will be able to obtain effective tax relief on future decommissioning costs. This policy measure, announced in last year's Budget, should help create a more active transactions market in UK oil and gas sector, and enable licence interests to be moved into the hands of the companies who wish to invest in the underlying assets.
Thursday 1st November
BP more than double it profits over the Third Quarter
BP has doubled its profits over the third quarter after benefiting from higher oil prices. The oil major said underlying replacement cost profit, rose to £2.9 billion over the three-month period, up from £1.4 billion in the same quarter last year. Oil and Gas production during the third quarter averaged 3.6 million barrels of oil per day. Revenue during the quarter rose to £63 billion, up substantially from £47.5 billion in the same period last year. BP has plans to develop the Alligin field, 140 km west of Shetland, targeting 20 million barrels of oil equivalent and giving the North Sea a £230 million investment boost.
Friday 2nd November
BP completes $10.5 billion BHP acquisition
BP has completed its acquisition of BHPs U.S unconventional assets in a huge deal that will upgrade BPs U.S onshore oil and gas portfolio helping to drive long term growth. The acquisition was announced in July and closed on Wednesday 31st of October. This acquisition adds oil and gas production of 190,000 boed and 4.6 Bboe of discovered resources in the liquids-rich regions of the Permian and Eagle Ford basins in Texas and in the Haynesville natural gas basin, in East Texas and Louisiana. The transaction is accredited to generate more than $350 million of annual pre tax synergies and is expected to boost Upstream free cash flow by $1 billion.
UnaCom Pharma News
29th October – 4th November
Monday 29th October
AstraZeneca is collaborating with Medicines Discovery Catapult for Acoustic Mist Ionisation Mass Spectrometry
AMI-MS introduces a twenty-fold improvement in throughput compared to traditional mass spectrometry. AMI use sound energy to introduce the sample into the detector rather than via a needle. A mist of charged droplets are lifted from the surface of a sample into the mass spectrometer. This method is contactless and contamination free with a sample being able to be analyzed every three seconds.
“This deal will allow small, medium enterprises (SME) access to the state-of-the-art bio analytical technology through research partnerships with Catapult. The collaboration will allow AstraZeneca to further unlock the potential of Acoustic Mist Ionisation Mass Spectrometry (AMI-MS) by accessing Medicines Discovery Catapults technical expertise” said the organisation.
Tuesday 30th October
The Accelerated Access Collaborative (ACC) has announced its first Rapid Uptake Products for the NHS
The ACC has announced that Roche's Diagnostic tests for suspected pre-eclampsia and heart attacks have been recognized and have been selected among the seven Rapid Uptake products for the NHS. The ACC brings together leaders from the Government, NHS and life sciences industry to drive forward innovation in the NHS. With work towards recognizing ideas that would be the most transformative for the NHS.
Roche's diagnostic tests have been recommended by NICE for use in clinical practices. The tests are simple blood tests that help clinicians quickly decide on the right course of action. These tests can also help alleviate pressure on the NHS resources by focusing efforts where they are most needed.
Wednesday 24th October
Medidata has teamed up with Pharm-OlamMedidata and Pharm-Olam have signed a new five-year deal to unify operational systems supporting study execution on Medidata Cloud. Pharm-Olam used to use multiple systems, leading to duplications of data when needed which would then require further integration later. With the introduction of Medidata, Pharm-Olam will be able to have all its data unified. It will help reduce costs for Pharm-Olam and provide better services to its customers.
Thursday 1st November
Gilead experiences dip in revenue but continues to raise outlook for the rest of the year
Gilead’s revenue beat expectations for the third quarter, despite experiencing a loss from last years results, leading the company to boost its earnings expectations for the rest of the year. Total revenues were $5.6 billion in 2018 compared to $6.5 billion in 2017. While Net income was $2.1 billion compared to $2.7 billion. Total product sales for the third quarter of 2018 were $5.5 billion compared to $6.4 billion for the same period in 2017.
UnaCom Oil and Gas News
Monday 15th October
Australia's BHP raises stakes in Ecuador copper project
BHP, the world’s biggest miner, increased its share in in SolGold Plc, as it eyes SolGolds lucrative copper-gold project in Ecuador, competing against top shareholder Newcrest Mining. SolGold will issue 100 million shares to the company, raising its stake to 11.2% from 6.0%. BHP has promised to pay 45 pence per SolGold share, an 8% premium to the closing stocks on Monday. With current top shareholders Newcrest Mining having a 14.54% stake. This deal strengthens the strategic position of BHP in this copper project.
Tuesday 16th October
Oil prices fall amid higher US supply
Oil prices fell today after news of higher US oil production and increasing U.S Crude inventories however a fall in Iranian oil exports helped to offset the fall. Brent crude oil was down by 50 cents a barrel at $80.28 and US light crude was down by 50 cents at $71.28. Shale oil production continues unperturbed, with oil production from seven major U.S Shale basins it is expected to rise by 98,000 barrels per day to a record of 7.71million bpd. In the first two weeks of October, Iran exported 1.33 million bpd of crude. This was down from 1.6 million bpd during the same period in September. This is a sharp decrease from the 2.5 million bpd in April before Trump ordered the re-imposition of sanctions.
Friday 18th October
OPEC struggling to add barrels to the market, to fulfill pledged oil output boost
A recent internal document has shown that OPEC is struggling to add barrels to the market, after pledging in June to increase output. The document showed that although there was an increase in Saudi Arabia production it was offset by declines in Iran, Venezuela and Angola. A pledge was made in June after President Trump urged producers to increase their output to offset sanctions that are to take place in Iran and to dampen prices. Following the June agreement Saudi Energy Minister Khalid al-Falih said OPEC and non-OPEC would pump roughly an extra 1 million barrels per day. Saudi Arabia pumped most of the extra oil, raising output by 524,000 bpd in September compared to May. Iran cut production by 376,000 bpd in September versus May and has said OPEC and Saudi Arabia are not able to make up for a total loss of its exports. Production also fell in Venezuela and Angola by 189,000 bpd and 17,000 bpd in Angola respectively.
Pharma Product News
October – 21st October
Karuna Pharmaceuticals has started its Phase two trial of KarXT, a drug being developed for the treatment of Schizophrenia
Karuna Pharmaceuticals is an affiliate of UK Biotech firm PureTech Health. KarXT consists of xanomeline a receptor with proven efficacy in placebo-controlled human trials in Schizoprenia and Alzheimers disease and trospium chloride an FDA approved receptor antagonist that has been shown not to enter the central nervous system. In the first phase study, KarXT successfully demonstrated tolerability at a dose level exceeding those shown to be efficacious in previous studies of xanomeline alone. Data from this study supported the dosage selection to be used in the second trial, which has the aims of reproducing efficacy results previously observed in a schizophrenia trial with xanomeline monotherapy. If this treatment were to succeed in passing clinical trials Karunas chief executive Steve Paul said that the treatment “could be effective in treating not only positive symptoms but also the disabling negative and cognitive symptoms of the disease.”
Wednesday 17th October
NHS greenlight Novartis skin care combo
The NHS has three months to ensure that Novartis skincare combination therapy dabrafenib/trametinib is available to skin cancer patients. NICE has recommended this combination for patients with stage III BRAF V600 mutation-positive melanoma, whose disease has spread to their lymph nodes or their lymph glands and who have had surgery to remove the tumour and associated lymph glands. This patient group have never had any other treatments with only surgery and radiotherapy available in certain cases. The aim of Novartis’ adjuvant therapy is to remove any residual cancer left behind to prevent recurrence. Clinical trials have shown that patients taking dabrafenib plus trametinib had higher rates of relapse-free survival (88% at 1 year, 67% at 2 years, and 58% at 3 years) compared with patients taking the placebo (56% at 1 year, 44% at 2 years, and 39% at 3 years). This provides a huge step forward for patients who have very few options left following surgery.
Friday 19th October
NICE rejects Eli Lilly’s breast cancer drug Verzenios
Eli Lilly’s cancer drug will not be funded by the NHS, after cost regulators released draft guidelines rejecting the drug. NICE states that Verzenios is just as effective as the current treatment being used, but when the patient access schemes are considered Verzenios is not as cost effective as the others being currently used. Verzenios was approved in Europe for the treatment of certain metastatic breast cancers earlier this month, based on data from the Phase 111 MONARCH 2 and 3 trials.
In MONARCH 2, Verzenios combined with AstraZeneca’s Faslodex, was found to considerably progression free survival compared to Faslodex on its own, with figures of 16.4 months versus 9.3 months respectively.
With the global shutdown that has occurred due to COVID-19, its presence has caused long-lasting effects in all aspects of our lives and t...
UnaCom Product News Round Up ...
The Competitions Market Authority (CMA) has raised concerns that the proposed merger between Illumina and Pacific BioSciences will lea...
This would be the first federal trial for the case in the US, despite attempts from J&J to avoid this scenario as it tried to negotiat...
After continuous delay there finally seems to be progress for the clearance of this $4.3bn deal by the FTC. According to reports made by...
AZ’s lung cancer drug Tagrissio has already established itself as AZ top selling medicine, in the third quarter it grew sales by over 13.6...